Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanofi d.o.o. - пропорциональному protiv difterije, pertusisa, poliomijelitisa, tetanusa - suspenzija za injekciju - ≥ 30 d'ag'u/0.5 ml+ ≥ 40 md'ag'u/0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml - 0,5 ml (1 doza) suspenzije sadrži: ≥ 30 i.j. toksoida difterije, prečišćeni + ≥40 i.j. toksoida tetanusa, prečišćeni + 25 mcg antigena bordetella pertussis toksoid + 25 mcg antigena bordetella pertussis filamentozni hemaglutinin + 40 jedinica d antigena tip 1 poliomijelitis virus, inaktivisani + 8 jedinica d antigena tip 2 poliomijelitis virus, inaktivisani + 32 jedinice d antigena tip 3 poliomijelitis virus, inaktivisani

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanofi d.o.o. - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ ≥ 25 µg/0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml+ 10 µg/0.5 ml - 0,5 ml (1 doza ) pripremljene suspenzije sadrži: ≥ 30 i.j. prečišćeni toksoid difterije; ≥40 i.j prečišćeni toksoid tetanusa; 25 mcg antigen bordetella pertussis toksoid; 25 mcg antigen bordetella pertussis filamentozni hemaglutinin; 40 jedinica d antigena tip 1 poliomijelitis virus, inaktivisani; 8 jedinica d antig tip 2 poliomijelitis virus, inaktivisani; 32 jedinica d antigena tip 3 poliomijelitis virus, inaktivisani; 10 mcg polisaharid haemophilus influenzae tip b, konjugovani

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - tetanus toksoid, kombinacije sa toksoidom difterija - suspenzija za injekciju u napunjenom špricu - 2 i.j./0.5 ml+ 20 i.j./0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenom špricu sadrži: ≥ 2 i.j. toksoida difterije i ≥ 20 i.j. toksoida tetanus adsorbirani na aluminijumhidroksidu, hidratnom 0,6 mg al

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanofi d.o.o. - virus пропорциональному protiv poliomijelitisa, trivalentna, inaktivisana, cijeli - suspenzija za injekciju - 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml - 0,5 ml suspenzije za injekciju (1 doza) sadrži: 40 dantigen jedinica virus poliomijelitisa tip 1, mahoney soj (inaktiviran) 8 dantigen jedinica virus poliomijelitisa tip 2, mef1 soj (inaktiviran) 32 dantigen jedinica virus poliomijelitisa tip 3, saukett soj (inaktiviran)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanofi d.o.o. - oralna пропорциональному protiv poliomijelitisa, bivalentna, ziva atenuisana - oralna suspenzija - ≥ 6 log10dozna forma/0.1 ml+ ≥ 5.8 log10dozna forma/0.1 ml - svaka doza od 0,1 ml (dvije kapi) oralne suspenzije sadrži: virus poliomijelitisa tip 1*, ls c 2ab soj (živi oslabljeni), najmanje 6.0 log† ccid50 ‡ virus poliomijelitisa tip 3*, leon, soj 12a 1b (živi oslabljeni), najmanje 5.8 log† ccid50 ‡ *proizvedeno u vero celijama † prethodno izraženo kao minimalno 10 x ccid50 ‡ccid50:50% ćelija kultivirane infektivne doze (jedinica virusne infekcije)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanofi d.o.o. - пропорциональному protiv difterije, poliomijelitisa, tetanusa (inaktivirana), adsorbovana - suspenzija za injekciju u napunjenoj šprici - ≥ 2 i.j./0.5 ml+ ≥ 20 i.j./0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml - jedna doza od 0,5 ml suspenzije za injekciju u napunjenoj šprici sadrži: difterija toksoid ≥ 2 iu tetanus toksoid ≥ 20 iu poliomijelitis virus (inaktivirani) tip 1 poliovirus (mahoney soj) 40 du tip 2 poliovirus (mef1 soj) 8 du tip 3 poliovirus (saukett soj) 32 du (1) adsorbirano na aluminijum hidroksid (0,35 mg)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenom špricu sadrži: 15 mcg ha** a/california/7/2009 (h1n1)pdm09sličan soj (a/california/7/2009,nymc x179a) 15 mcg ha 15 mcg ha** a/texas/50/2012 (h3n2)sličan soj (a/texas/50/2012,nymc x223a) 15 mcg ha** b/massachusetts/2/2012 (yamagata lineage) 15 mcg ha** b/brisbane/60/2008 (victoria lineage) *proizveden u oplođenim jajima kokoški iz zdravih jata ** hemaglutinin

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - influenca, inaktivisana, fragmentisani virus ili površinski antigen - suspenzija za injekciju u napunjenoj šprici - 15 µg/0.5 ml+ 0,5 µg/0.5 ml+ 15 µg/0.5 ml+ 15 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenom špricu sadrži: 15 mcg ha** a/california/7/2009 (h1n1)pdm09sličan soj (a/california/7/2009,nymc x179a) 15 mcg ha 15 mcg ha** a/texas/50/2012 (h3n2)sličan soj (a/texas/50/2012,nymc x223a) 15 mcg ha** b/massachusetts/2/2012 (yamagata lineage) 15 mcg ha** b/brisbane/60/2008 (victoria lineage) *proizveden u oplođenim jajima kokoški iz zdravih jata ** hemaglutinin

Europska Unija - hrvatski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokal - cjepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.